• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Tweets & Drugs & Rock n’ Roll


Peter Houston was surprised to find himself discussing Turing Pharmaceutical’s Daraprim in the offices of ClassicRock magazine last week. What’s even more surprising was impact the price hike on the toxoplasmosis treatment was having on a punk record label.

I don’t remember ever, outside of my time with Pharm Exec, having a conversation about drug pricing. To be honest, I never really had a drug pricing conversation at Pharm Exec – I just listened to people that knew way more than I did (everyone).

Peter Houston

Imagine my surprise when I found myself discussing the pricing of Turing Pharmaceutical’s Daraprim in the London offices of the iconic ClassicRock magazine. What’s even more surprising was that the discussion centred on the impact a 5,000 percent price hike on the toxoplasmosis treatment was having on a punk record label.

Wednesday morning, I was walking across the newsroom at TeamRock, the publisher of a portfolio of Rock and Metal music magazines that includes ClassicRock, and staring out from the Teamrock.com home page, was the face of Turing’s 32-year old CEO Martin Shkreli.

It turned out that Shkreli - newly crowned ‘The most hated man on the Internet’ - has a minority shareholding in the Collect record label run by Geoff Rickly, the New Jersey-born front man of the band No Devotion. Rickly had just been interviewed about his relationship with Shkreli and he was not happy.

Explaining that he feared for the future of his business, the singer and label boss said, "Never in a million years did any of us expect to wake up to the news of the scandal that he is now involved in.” The label cut ties ‘immediately’.

I have no doubt Rickly ended his business relationship with Shkreli based on his and his colleagues own views of the rights and wrongs of putting a $750 price tag on a pill that previously cost less than $15. But the collective howl of disapproval sent up by social media when the story broke must have made their decision to split from their erstwhile financial backer very straight forward.

As online magazine Salon put it, ‘Shkreli was shredded on Twitter’.

Interestingly it was a tweet from Democratic presidential hopeful Hilary Clinton that seems to have started the social snowball rolling. On Monday, responding to a New York Times story on the Daraprim price increase, the former FLOTUS tweeted: “Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on.”

Before anyone saw that plan, Biotech stocks were down almost 5 percent and the internet was hating hard on Shkreli.

Every drug company executive that reads Pharm Exec regularly, even the few that don’t, know formulating drug pricing strategies is almost as complicated as formulating the drugs themselves. But as far as the internet was concerned last week, someone was trying to take a drug that cost pennies to manufacture and gouge chronically ill HIV sufferers for hundreds of thousands of dollars.

The general reporting was harsh; work your way through the thousands of tweets, Facebook posts and article comments about what Shkreli did and you worry that the security bill for keeping him safe will be higher than any additional money he could ever make from Daraprim.

One ill-judged pricing decision by a serially controversial entrepreneur who has since backtracked on his price increase might appear to be minor matter for Big Pharma. But read the comments closely: Martin Shkreli is seen as the personification of pharma greed.

This isn’t just about one silly CEO, this is about pharma.

The original Times story devotes almost as much space to other instances of perceived price gouging as it does to Shkreli and Daraprim. And online headlines in several mainstream publications don’t demure from dragging Pharma in.

The Atlantic – Pharma Bro Is the Face of U.S. Health Care

Forbes – What we should learn from Pharma’s latest monster

The Daily Beast - Martin Shkreli Is Big Pharma’s Biggest A**hole

Vox ironically cast Shkreli as an ‘American hero’, writing: “Pharmaceutical companies have been buying up generic drugs, jacking up their prices, and messing up patients' lives for years.” They said America should be thanking Shkreli because, “No one cared about it until Shkreli appeared on the national scene this week.” And now they do.

While Big Pharma has dealt with public irritability over drug pricing for years, this feels a little different. It feels different because it’s an election year. It feels different because there’s what the Atlantic calls an ‘easily dislikeable villain’ to fix existing resentments on. And it feels different because of social media: This story took off like a rocket; so much so that even the rock fans of the UK have a view and almost 220,000 people have signed an online petition that demands a full price reversal.

In all the coverage of this story, the best advice for Pharma comes from Forbes science and medicine correspondent Mathew Herper. Referencing Murray Aitken of IMS asking ‘What should drugs cost?’ at last year’s Forbes Healthcare Summit, he says that to ‘contain the damage Shkreli caused’ pharmaceutical executives need to get better at explaining and justifying how they arrive at the price of drug prices.

Herper also suggests that leaving drug pricing to the political process is dangerous. I’d argue that leaving it to social media is even worse.

Recent Videos
Related Content